New imaging technique targets Hard-to-Find cancers
NCT ID NCT05737615
First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 4 times
Summary
This study aimed to test a new two-step PET imaging method to better detect cancers that produce a substance called CA19-9, such as pancreatic, bladder, and gastrointestinal tumors. The plan was to give patients an antibody followed by a radioactive tracer to highlight cancer cells. However, the trial was withdrawn before any patients were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hu5B1-TCO and 64Cu-Tz-SarAr
- What this could lead to
- If successful, this could lead to a more precise way to detect certain cancers using PET scans.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no results are available. The approach is still very early and unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new drug combo shrink Hard-to-Treat tumors?